Data gathered: March 21
AI Stock Analysis - Lantheus (LNTH)
Analysis generated November 15, 2024. Powered by Chat GPT.
Lantheus Holdings, Inc. is a prominent player in the healthcare sector, primarily specializing in diagnostic imaging agents and products. The company provides medical imaging solutions that help healthcare professionals diagnose and treat diseases more effectively. Lantheus’ portfolio includes nuclear imaging, ultrasound contrast agents, and other imaging products. Given its critical role in the healthcare diagnostics market, Lantheus is well-positioned to benefit from the ongoing advancements in medical technologies.
Stock Alerts - Lantheus (LNTH)
 |
Lantheus | March 20 Price is down by -5% in the last 24h. |
|
Lantheus | March 20 Insider Alert: Marshall Robert J. Jr. is selling shares |
|
Lantheus | March 18 Insider Alert: Heino Mary Anne is continuing selling shares |
|
Lantheus | March 17 AI Score is down by 20.5% in the last couple of days. |
Alternative Data for Lantheus
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 59 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 24,000 | Sign up | Sign up | Sign up |
| Employee Rating | 64 | Sign up | Sign up | Sign up |
| Google Trends | 23 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 13 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,513 | Sign up | Sign up | Sign up |
| Twitter Followers | 382 | Sign up | Sign up | Sign up |
| Twitter Mentions | 23 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $60,000 | Sign up | Sign up | Sign up |
| Business Outlook | 63 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,151 | Sign up | Sign up | Sign up |
About Lantheus
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
| Price | $95.40 |
| Target Price | Sign up |
| Volume | 404,070 |
| Market Cap | $7B |
| Year Range | $76.22 - $123.42 |
| Dividend Yield | 0% |
| PE Ratio | 23.45 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Lantheus price target lowered to $122 from $127 at B. RileyMarch 21 - Thefly.com |
 |
PNC Financial Services Group Inc. Trims Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)March 19 - ETF Daily News |
 |
Is Lantheus Holdings, Inc. (LNTH) the Best Healthcare Stock For Long-Term Investment?March 14 - Yahoo |
|
Raymond James Financial Inc. Invests $36.18 Million in Lantheus Holdings, Inc. (NASDAQ:LNTH)March 14 - ETF Daily News |
|
Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by Arizona State Retirement SystemMarch 12 - ETF Daily News |
|
Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Charles Schwab Investment Management Inc.March 12 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 379M | 233M | 242M | 131M | 189M | 1.700 |
| Q2 '24 | 394M | 241M | 256M | 62M | 92M | 1.800 |
| Q1 '24 | 365M | 232M | 242M | 131M | 186M | 1.690 |
| Q4 '23 | 349M | 237M | 230M | 103M | 181M | 1.750 |
| Q3 '23 | 315M | 196M | 200M | 132M | 168M | 1.470 |
Insider Transactions View All
| Marshall Robert J. Jr. filed to sell 113,860 shares at $100.5. March 19 '25 |
| Heino Mary Anne filed to sell 8,618 shares at $100.1. March 17 '25 |
| Blanchfield Paul filed to sell 91,828 shares at $98. March 7 '25 |
| Heino Mary Anne filed to sell 440,399 shares at $95.9. March 5 '25 |
| Heino Mary Anne filed to sell 487,241 shares at $92.3. March 5 '25 |
Similar companies
Read more about Lantheus (LNTH) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Lantheus?
The Market Cap of Lantheus is $7B.
What is Lantheus' PE Ratio?
As of today, Lantheus' PE (Price to Earnings) ratio is 23.45.
What is the current stock price of Lantheus?
Currently, the price of one share of Lantheus stock is $95.40.
How can I analyze the LNTH stock price chart for investment decisions?
The LNTH stock price chart above provides a comprehensive visual representation of Lantheus' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Lantheus shares. Our platform offers an up-to-date LNTH stock price chart, along with technical data analysis and alternative data insights.
Does LNTH offer dividends to its shareholders?
As of our latest update, Lantheus (LNTH) does not offer dividends to its shareholders. Investors interested in Lantheus should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Lantheus?
Some of the similar stocks of Lantheus are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.